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ABSTRACT 
Simvastatin is a Hypolipidemic used to control elevated cholesterol or hypercholesterolemia. The primary uses of simvastatin are for 
the treatment of dyslipidemia and the prevention of cardiovascular disease. Gastroretentive Floating tablets of Simvastatin were 
developed by direct compression method using HPMC K15M, HPMC K100M, Carbopol, sodium CMC, xanthan gum, sodium 
alginate polymers used and the mixture of the sodium bicarbonate, citric acid anhydrous as gas generating agents. The results of Pre-
compressional and post compression parameters were within IP prescribed limits. The formulation FC1, FC2, FC3, FC4, FC5, FC6, 
FC8 floated but the lag time was more and floating time is less. For the formulation FC7, the duration of buoyancy was more than 12 
hrs, the floating capacity increased in these formulations and floated with less lag time due to the high concentration of gas 
generating agent sodium bicarbonate-induced CO2 generation in the pressure of dissolution medium (pH 1.2 0.1N HCL). The drug 
release from the formulations FC1-FC8 was found to be 78.612, 72.66, 87.22, 63.45, 67.26, 73.24, 98.93, and 81.27 in 12hrs. 
Among all the formulations FC7 floating lag time 7 min with 99% of drug release has better control release of the drug. DSC and 
FTIR studies revealed that there was no incompatibility of the drug with the excipients used. The stability study conducted as per the 
ICH guidelines and the formulations were found to be stable. From this study, it can be concluded that the formulation retained for 
longer periods of time in the stomach and provides controlled release of the drug and may improve bioavailability. 
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Poor bioavailability has been recorded for some drugs 
formulated in sustained-release dosage forms. Their 
narrow absorption window, lower solubility at high pH 
values, or enzymatic degradation in the intestinal or 
colonic environments was the reason of decreased 
bioavailability
1-5
. For this, it has been a challenge to 
develop the oral controlled-release dosage form because 
it is difficult to keep drugs at the targeted area inside the 
gastrointestinal tract
6
. Gastro retentive drug delivery 
systems provide dosage forms with a longer residence 
time in the stomach and sustained-release behavior, 
which can improve bioavailability as well as the acting 
locally on the stomach
7,8
. Increasing gastric residence 
time can be achieved either by floating systems that 
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cause buoyancy above gastric fluid
9
, high-density 
systems that sink to the bottom of the stomach
10
, 
bioadhesive systems that adhere to mucosal surfaces
11
, 
or by expandable systems that have limited emptying 
through the stomach pylorus due to swelling or 
unfolding to a larger size
12
. 
The floating drug delivery systems were described in the 
literature as early as 1968
13
. These systems are designed 
to have a bulk density lower than the gastric fluid so 
they can remain buoyant for prolonged periods of time 
without affecting the gastric emptying          rate
3,14,15
. 
Floating drug delivery systems can be classified as non-
effervescent systems or effervescent systems
16
. Non-
effervescent floating drug delivery systems swell in 
gastric fluid and maintain a relative stability of shape 
and a bulk density less than the density of the gastric 
fluid, which assists the floating process of these dosage 
forms
17
. However, effervescent floating drug delivery 
systems based on effervescent components will liberate 
carbon dioxide due to the acidity of the gastric fluid. 
Liberated gas bubbles will be entrapped in the gel layer 
formed by hydrocolloids that produce an upward motion 
of the dosage form and maintain its buoyancy
18
. 
Simvastatin is a Hypolipidemic used in management of 
elevated cholesterol or hypercholesterolemia. It is a 
member of the Statin class of pharmaceuticals. The 
primary uses of simvastatin are for the treatment of 
dyslipidemia and the prevention of cardiovascular 
disease. The t1/2 for Simvastatin is 2 to 4 hrs and 
bioavailability is 5% and efficiency of protein binding is 
95%. This study provided valuable information on 
preformulation and formulation optimization of the 
selected anti-retroviral drugs as floating modules during 
the development of controlled drug delivery systems 
containing various rate controlling polymers, to get the 
desired controlled release over a period of 12 hrs. The 
main objective of the present research work is 
formulation and development of floating drug delivery 
system containing Simvastatin, which releases the drug 
at controlled rate for a long period of time in the 
stomach. The present investigation concerns the 
Gastroretentive tablets of Simvastatin were by direct 
compression technique using polymers like HPMC 
K15M, HPMC K100M, HPMC 5 cps, Carbopol, sodium 
CMC, xanthan gum, sodium alginate polymers used and 
the mixture of sodium bicarbonate, citric acid anhydrous 
as gas generating agents, MCC, lactose as fillers.  
MATERIALS AND METHODS:  
Simvastatin drug is procured as a gift sample from 
Lupin labs, Private Ltd. Pune, India. HPMC K4M 
procured as a gift sample from AstraZeneca Pvt Ltd 
Bangalore. Carbopol 934, xanthan gum (XG), hydroxyl 
ethyl cellulose (HEC), magnesium stearate and citric 
acid are purchased from Hi media laboratories Pvt. Ltd, 
Mumbai. India, Sodium bicarbonate, sodium alginate, 
lactose, mannitol and talc were purchased from S.D. 
Fine Chemicals. Mumbai. All other materials used were 
of pharmaceutical grade. 
Drug-excipients compatibility studies: Fourier 
Transform Infrared Spectroscopy (FTIR) and 
Differential Scanning Colorimetry. 
Fourier Transform Infrared Spectroscopy (FTIR): 
FTIR studies were carried out pure drug Simvastatin and 
best formulations like, FC6 and FC7. Infrared 
spectroscopy was performed using a Shimadzu FTIR 
8300 Spectrophotometer and the spectrum was recorded 
in the region of 4000 to 400 cm
-1
. The procedure 
consisted of dispersing a sample (drug and excipients, 
1:1 ratio in potassium bromide (KBr) (200-400 mg) and 
compressing into discs by applying a pressure of 5 tons 
for 5 min in a hydraulic press. The pellet was placed in 
the light path and the spectrum was obtained.  
Differential Scanning Colorimetry: DSC studies were 
carried out pure drug Simvastatin and formulations like, 
FC6 and FC7. DSC scan of about 5mg accurately 
weighed Simvastatin and other formulations were 
performed by using an automatic thermal analyzer 
system. (DSC60 Shimadzu Corporation, Japan) Sealed 
and perforated aluminium pans were used in the 
experiments for all the samples. Temperature 
calibrations were performed using indium as standard. 
An empty pan sealed in the same way as for the sample 
was used as a reference. The entire samples were run at 
a scanning rate of 10°C/min from 50-300°C. 
 
 
Table 1: Formulations of Simvastatin Floating tablets 
INGREDIENTS FC1 FC2 FC3 FC4 FC5 FC6 FC7 FC8 
Drug 40 40 40 40 40 40 40 40 
Sodium bi carbonate 40 40 40 40 50 50 60 50 
Xanthan gum 10 10 10 10 10 10 10 10 
Sodium alginate 10 10 10 10 10 10 10 10 
Sodium CMC 20 20 30 30 20 20 30 30 
HPMC K15m 20 30 20 30 20 30 20 30 
HPMC K100m 10 10 10 10 10 10 10 10 
Citric acid 5 5 5 5 5 5 5 5 
Carbopol - - - - 20 30 30 20 
Talc 10 10 10 10 10 10 10 10 
Magnesium stearate 10 10 10 10 10 10 10 10 
MCC 65 55 55 45 35 15 05 15 
Total 300 300 300 300 300 300 300 300 
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Preparation of Simvastatin floating tablets
19-20
: All 
the formulations FC1 to FC8 were prepared by direct 
compression method. The composition of the tablets is 
given in Table 1. All the formulation tablets containing 
drug and other excipients, were prepared by weighing 
drug, diluents along with natural gums and passing them 
through sieve no 44 to break the lumps and also for 
proper blending of powder, to this powder blend 0.5 % 
of magnesium stearate and 1 % of talc were added to 
each and further mixed. The resultant blends were 
punched to 300 mg using convex-faced punches using a 
multi-station rotary compression machine (Rinek mini 
press-II MT). 
The resultant blends were evaluated for pre-
compressional parameters to find out the flow properties 
of powder blend. The pre-compressional parameters 
such as Bulk density, Tapped density, Angle of repose, 
Compressibility index and Hausner ratio. 
Evaluation of Simvastatin floating tablets
21-24
: 
Weight Variation Test: Weigh 20 tablets selected at 
random and calculate the average weight. Not more than 
two of the individual weights deviate from the average 
weight by more than the percentage limits. As per Indian 
Pharmacopoeia specification.          
Friability Test: 20 tablets were weighed and subjected 
to rotate on friability test apparatus. The drum rotated at 
a speed of 25 rpm for 4 minutes, then dedusted and 
reweighed the tablets. Percentage friability was 
calculated. Percentage friability of tablets less than 1% is 
considered acceptable.  
Hardness Test: The hardness of tablet was carried out 
by using Pfizer type hardness tester. The hardness of the 
tablet kg / cm² was measured.  
Thickness Test: Control of physical dimension of the 
tablets such as sizes and thickness is essential for 
consumer acceptance and to maintain tablet to tablet 
uniformity. The dimensional specifications were 
measured using verniar calipers. Six tablets from each 
batch were tested and average values were calculated. 
The thickness of the tablet is mostly related to the tablet 
hardness can be uses as initial control parameter. 
Buoyancy lag time (BLT): The time taken for dosage 
form to emerge on surface of medium is called floating 
lag time (FLT) or buoyancy lag time (BLT). 
Determination of in-vitro floating lag time: The in-
vitro buoyancy was determined by floating lag time and 
total floating time, as per the method. In a 250 ml beaker 
containing buffer solution, maintained at 37 ± 0.5°C in a 
water bath. Their physical state was observed for 24 h. 
The time required for the tablet to rise to the surface and 
float was determined as floating lag time and total 
duration of time by which dosage form remain buoyant 
is called total floating time. 
In-vitro dissolution studies: The release rate of 
Simvastatin from floating tablet was determined by 
Dissolution Tester apparatus DS-8050 Lab India. The 
dissolution test was performed using 900ml 0.1N HCL 
with 1% sodium lauryl sulphate at 37°C ± 0.5
0
C. At 
each hour interval, aliquots of 10 ml were withdrawn 
from the dissolution medium and the amount was 
replaced with fresh medium to maintain the volume 
constant. The samples were filtered through a Whatmaan 
filter paper and diluted to a suitable concentration with 
dissolution media for the study. The absorbance of the 
solutions was measured at 236 nm. Cumulative 
percentage of drug release was calculated using an 
equation obtained from the standard curve. 
Determination of swelling index: The swelling index 
of tablets was determined in 0.1N HCL (with 1%SLS) at 
37ºC temperature. The swollen weight of the tablet was 
determined at predefined time intervals over a period of 
5hr. The swelling index (SI) is expressed as a percentage 
and was calculated from the following equation. 
               
     
  
     
Stability Studies: Stability studies were performed on 
optimised formulation, prepared tablets were wrapped 
with aluminium foil and kept in a vial. These samples 
were placed in a stability chamber (Thermolab, humidity 
and photo stability chamber) at 40±2
0 
C and 75±5% RH 
according to ICH guidelines. At regular time intervals of 
15, 30, 60 and 90 days tablets were analysed for drug 
release lag time. 
RESULTS AND DISCUSSIONS: 
Drug - Excipient compatibility studies: 
FTIR Studies: The FT-IR spectra of pure drug peaks 
are observed in the Simvastatin sample and formulations 
were showed same characteristic absorption bands at or 
near that of Simvastatin absorption bands values 
indicating that there was no chemical and physical 
change in the functional groups present in Simvastatin. 
[Shown in Fig 1]. 
DSC Studies: The study also reveals that the 
thermogram of pure drug and other formulations [Shown 
in Fig 2] shows negligible changes in the melting point 
range.  Thus the DSC thermograms study reveals that 
there is no any kind of interaction of the drug with 
different types of polymer and their excipients used 
during the study. 
Evaluation of Simvastatin gas powered tablets:  
The Pre-compression parameters were the primary 
requirements to determine whether the specific material 
was suitable for the targeted formulation or not. The aim 
was to formulate the tablet formulation with direct 
compression method, so it was mandatory to know the 
bulk density, tapped density, Carr’s index, Hausner’s 
ratio and angle of repose as those were the official 
requirement while choosing any material for its dosage 
form formulation. The results evaluated pre-compression 
parameters for various tablet formulations. The results 
clearly indicate its suitability to be the material of choice 
for formulation. The values were within prescribed 
limits and indicated good free-flowing property. The 
results of pre-compression parameters were given in 
Table 2. 
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Figure 1: IR spectra of pure drug Simvastatin and optimized formulations FC6 and FC7. 
  
Figure 2: DSC Thermograms of pure drug Simvastatin and optimized formulations FC6 and FC7. 
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0.05’ ± 0.12 0.462 ± 0.03 0.56 ± 0.01 12.64 ± 0.05 1.13 ± 0.06 
FC2 28
0.24’ ± 0.11 0.546 ± 0.01 0.67 ± 0.02 21.62 ± 0.06 1.24 ± 0.04 
FC3 26
0.84’ ± 0.12 0.528 ± 0.02 0.54 ± 0.04 18.36 ± 0.05 1.22 ± 0.06 
FC4 28
0.24’ ± 0.15 0.468 ± 0.04 0.64 ± 0.03 25.36 ± 0.04 1.32 ± 0.04 
FC5 28
0.36’ ± 0.14 0.448 ± 0.02 0.54 ± 0.04 22.24 ± 0.05 1.24 ± 0.08 
FC6 29
0.22’ ± 0.12 0.346 ± 0.06 0.66 ± 0.05 11.64 ± 0.04 1.14 ± 0.06 
FC7 29
0.34’ ± 0.12 0.532 ± 0.04 0.56 ± 0.06 11.46 ± 0.02 1.16 ± 0.02 
FC8 28
0.05’ ± 0.13 0.462 ± 0.04 0.46 ± 0.02 12.64 ± 0.06 1.13 ± 0.07 
FC=Formulation code *All the values expressed as mean ± SD, n=3 
 
All the prepared batches were evaluated systematically. 
The obtained results of the evaluated post compression 
parameters were represented in in Table 3. The results of 
all the trial batches were compared and found satisfactory, 
as per the reported specification. Finally, the comparison 
parameters were keenly observed to finalize for selection of 
the optimized batch and formula. The results of Post-
compressional parameters were within I.P prescribed 
limits. 
Water Uptake Study (Swelling Index): Tablets composed 
of polymeric matrices build a gel layer around tablets core 
when they come in contact with water. This gel layer 
governs the drug release. Kinetics of swelling is important 
because the gel barrier is formed with water permeation. 
Swelling is also a vital factor to ensure floating. To obtain 
floating the balance between swelling and water acceptance 
must be restored.
101
 Results of water uptake study showed 
that the order of swelling in these polymers could indicate 
the rates at which the preparations are able to absorb water 
and swell. Maximum liquid uptake and swelling of the 
polymer achieved up to 7 hrs and then gradually decreased 
due to erosion. The swelling of polymers used in this 
CGPS tablets (HPMC K4M, carbopol, sodium CMC, 
sodium alginate) could be determined by water uptake of 
the tablets. The complete swelling was achieved by the end 
of 7 hrs. 
 













variation  (mg)** 
Swelling index 
(%)** 
FC1 4.06  ± 0.056 6.3 ± 0.2 0.61 ±  0.07 83.65 299.66 ± 1.52 78.42 ± 0.45 
 FC2 4.17 ± 0.057 6.5 ± 0.3 0.64  ± 0.09 83.01 301.33 ± 2.51 98.20 ± 0.63 
FC3 4.14 ± 0.140 6.4 ± 0.1 0.65  ± 0.10 76.6 301.33 ± 2.08 110.40 ± 0.92 
FC4 4.28 ± 0.206 6.3 ± 0.1 0.60  ± 0.03 79.16 300.00 ± 2.00 108.20 ± 0.45 
FC5 4.23 ± 0.102 6.2 ± 0.3 0.64  ± 0.12 84.61 302.00 ± 1.00 96.40 ± 0.23 
FC6 4.22 ± 0.021 6.2 ± 0.1 0.60  ± 0.11 87.17 299.00 ± 1.00 102.10 ± 0.25 
FC7 4.19 ± 0.036 6.5 ± 0.1 0.64  ± 0.13 89.42 303.66 ± 1.50 95.76 ± 0.54 
FC8 4.20 ± 0.040 6.6 ± 0.1 0.69 ± 0.10 79.8 301.66 ± 2.08 104.48 ± 0.20 
FC=Formulation code, **All the values expressed as mean ±SD, n=20,                          *All the values expressed as mean ±SD, n=3. 
 
In-Vitro Buoyancy and Lag Time Study: The 
formulation FC1, FC2, FC3, FC4, FC5, FC6, FC8 
floated but the lag time was more and floating time is 
less. For the formulation FC7, the duration of buoyancy 
was more than 12 hrs, the floating capacity increased in 
these formulations and floated with less lag time due to 
the high concentration of gas generating agent sodium 
bicarbonate-induced CO2 generation in the pressure of 
dissolution medium (pH 1.2 0.1N HCL). The gas 
generation is trapped & protected within the gel formed 
by hydration of the polymers, thus decreasing the 
density of tablet. As the amount of polymer in the tablet 
formulation increases, the drug release rate decreases 
and as the concentration of gas generating agent 
(NaHCO3) increases the drug release increases and at 
the same time floating lags time decreases.  All the 
results were given in Fig 3. 
In-vitro Drug Release Studies of Simvastatin 
Formulations: The drug release from the formulations 
FC1-FC8 was found to be 78.612, 72.66, 87.22, 63.45, 
67.26, 73.24, 98.93, and 81.27 in 12hrs. Among all the 
formulations FC7 formulation shows the drug release 
around 98.93% within 12 hrs. From the in-vitro drug 
release study, it is found to be as the concentration of 
the polymer increases the drug release decreases. The 
dissolution profiles of all the formulations are shown in 
Fig 4-5. From results the formulation containing the 
large concentration of high viscosity polymers induced 
the formation of strong viscous gel layer that leads to 
decreased water diffusion into the tablet which results in 
decrease drug release. 
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Figure 3: Floating Time Vs Formulation FC1-FC8 
 
Figure 4: Release profile of formulations FC1-FC4 
 
Figure 5: Release profile of formulations FC5-FC8 
In-vitro drug release kinetic studies: A result showed 
in table 4 reveals that all formulations follow zero order 
kinetics as correlation coefficient (r
2
) values are higher 
than that of first order release kinetics. The calculated n 
values from power law equation for drug release profiles 
were between 0.870-0.997 with a correlation coefficient 
(r
2
) values >0.94, suggest that drug release mechanism 
from Simvastatin Floating tablets followed non-Fickian  
(anomalous) transport mechanism. 
 
Table 4: In-vitro Drug release kinetics of FC1-FC8 Formulation 
FC Zero Order R
2
 Value First Order R
2
 Value Higuchi R
2
 Value Peppas R
2
 Value Peppas  n value 
FC1 0.975 0.997 0.975 0.996 0.746 
FC2 0.982 0.998 0.973 0.998 0.748 
FC3 0.976 0.987 0.981 0.997 0.700 
FC4 0.987 0.997 0.964 0.989 0.737 
FC5 0.979 0.991 0.950 0.985 0.795 
FC6 0.983 0.994 0.963 0.991 0.752 
FC7 0.981 0.816 0.962 0.994 0.739 
FC8 0.980 0.992 0.974 0.996 0.713 
FC=Formulation code 
Table 5 shows the parameters of the tablets after 
stability study. The promising formulations were 
subjected to short-term stability study. The best 
formulations were selected.  After three months the 
tablets were again analyzed for the hardness, drug 
content uniformity and floating time. No significant 
changes in other parameters were observed in the tablets 
prepared with the different technique of all formulations 
was within the acceptable limits. 
 
Table 5: Stability study data 




 6.7 87.48 07min 34sec 
2
nd
 6.7 88.59 07min 55sec 
3
rd
 6.9 85.41 8min 
FC=Formulation code 
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CONCLUSION:  
Studies have been carried out to develop Gastroretentive 
tablets of Simvastatin with natural polymers HPMC 
K15M, HPMC100M, xanthan gum, Carbopol. The 
powder blend was evaluated for various Micromeritic 
properties. Eight different formulations were made and 
the formulations were tested for floating characterization 
like floating lag time and floating time, in-vitro 
dissolution studies. Based on the results of floating and 
dissolution studies FC7 formulation shows the drug 
release around 99% within 12 hrs. FC7 was found to be 
the best among trials. The formula FC7 floating lag time 
7 min with 99% of drug release has better control release 
of the drug. Finally, it can be concluded that the 
formulation retained for longer periods of time in the 
stomach (spatial control) and provides controlled release 
of the drug. Hence, Gastroretentive tablets retained for 
longer periods of time in the stomach which may lead to 
improves the therapeutic effect of the drug by increasing 
its bioavailability. 
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